期刊文献+

功能性消化不良根除幽门螺杆菌后症状改善相关因素分析 被引量:17

Analysis of the factors related with symptomatic improvement after Helicobacter pylori eradication in functional dyspepsia patients
原文传递
导出
摘要 目的探讨将治疗前胃黏膜组织学特征作为幽门螺杆菌(Hp)阳性功能性消化不良(FD)患者根除Hp后症状改善疗效预测指标的可能性,以提高消化不良患者的治疗水平。方法连续调查240例进行胃镜检查Hp阳性FD患者,其中190例接受三联抗Hp治疗,另50例作为对照,给予奥美拉唑治疗,疗程均为7d。治疗前胃黏膜组织学按新悉尼系统标准进行评估。治疗后1个月(治疗组和对照组)和6个月(治疗组)用C13-尿素呼气试验评估Hp。治疗前、治疗后1个月和6个月用消化不良调查表对症状程度进行评分,并计算仍有症状率,分析治疗前胃黏膜组织学与根除Hp后症状改善之间的相关性。结果Hp阳性FD患者分别有35·3%和42·6%在根除Hp后1个月和6个月消化不良症状改善显效,且根除Hp者症状缓解率显著高于Hp根除失败者(P<0·01);也高于对照组(P<0·01)。治疗前胃黏膜组织学指标中,炎症、活动性程度和Hp密度在根除Hp后症状改善显效的FD患者均显著高于有效和无效者(P<0·05)。多元回归分析支持上述组织学因素与根除Hp后症状显著改善相关。结论Hp阳性FD患者根除Hp后确实有部分患者症状显著改善。Hp阳性FD患者根除治疗前胃黏膜炎症、活动性程度和Hp密度能够预示根除Hp后症状改善的疗效。 Objective To improve the management of dyspepsia by evaluating the potential role of pretreatment gastric histology as predictive factors on the symptomatic response after Helicobacter pylori (H. pylori) eradication in patients with functional dyspepsia (FD). Methods 240 FD patients with H. pylori infection out of 920 consecutive patients receiving gastroendoscopy due to dyspepsia were investigated, including 190 patients enrolled as the therapy group and administered with anti-H, pylori triple therapy. In addition, 50 patients were enrolled as the control group, in which omeprazole was an alternative to the triple therapy. The course of therapy in both groups was 7 days. Pretreatment gastric histology was evaluated by the updated Sydney system. C^13 urea breath test was performed to evaluate the H. pylori eradication results one month (both therapy group and control group) and six months (therapy group) after therapy. For each patient, the baseline, month 1 and month 6 symptom scores were assessed by a questionnaire of dyspepsia, including 12 symptom items of dyspepsia with scoring of severity. The relationship between pretreatment gastric histology and good symptom responses after H. pylori eradication was then analyzed. Results Of 35. 3% and 42. 6% patients with successful H. pylori eradication in the therapy group had a good symptomatic response one month and six months after the triple therapy respectively, higher than those from the patients who failed H. pylori eradication ( month 1:35.3% vs 12. 2%, P 〈0.01 ; month 6:42. 6% vs 13.3%, P 〈0. 01 ) and those from the control group ( month 1:35.3% vs 13.6% , P 〈0. 01 ). Among the pretreatment gastric histologic indicators, the severity of inflammation and activity and the density of H. pylori were higher in patients with good symptom response than in patients with moderate or poor symptom response ( P 〈 0. 05 ), and the multivariate regression analysis confirmed the correlation. Conclusion Actually a certain subset ( about 1/ 3 ) of FD patients with H. pylori infection do have dyspeptic symptom improvement after H. py/or/ eradication. The pretreatment severity of inflammation and activity and the density of H. pylori in gastric mucosa of FD patients with H. pylori infection are helpful in predicting the symptomatic response after H. pylori eradication.
出处 《中华消化内镜杂志》 2006年第2期109-113,共5页 Chinese Journal of Digestive Endoscopy
基金 上海市重点学科建设项目资助(Y0205)
关键词 消化不良 螺杆菌 幽门 体征和症状 Dyspepsia Helicobacter pylori Signs and symptom
作者简介 通讯作者:刘文忠,Email:liuwzmd@163.com
  • 相关文献

参考文献14

  • 1Gisbert JP,Cruzado AI,Garcia-Gravalos R,et al.Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia.Randomized one-year follow-up study.Hepatogastroenterology,2004,51:303-308.
  • 2Veldhuyzen van Zanten S,Fedorak RN,Lambert J,et al.Absence of symptomatic benefit of lansoprazole,clarithromycin,and amoxicillin triple therapy in eradication of Helicobacter pylori positive,functional (nonulcer) dyspepsia.Am J Gastroenterol,2003,98:1963-1969.
  • 3Malfertheiner P,MOssner J,Fischbach W,et al.Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.Aliment Pharmacol Ther,2003,18:615-625.
  • 4Delgado-Aros S,Cremonini F,Talley NJ.Treatment of functional dyspepsia.Curr Treat Options Gastroenterol,2004,7:121-131.
  • 5McColl K,Murray L,El-Omar E,et al.Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.N Engl J Med,1998,339:1869-1874.
  • 6Hu WH,Lam KF,Wong YH,et al.The Hong Kong index of dyspepsia:a validated symptom severity questionnaire for patients with dyspepsia.J Gastroenterol Hepatol,2002,17:545-551.
  • 7Dixon MF,Genta RM,Yardley JH,et al.Classification and grading of gastritis:the updated Sydney system:International Workshop on the Histology of Gastritis,Houston 1994.Am J Surg Pathol,1996,20:1161-1181.
  • 8Delgado-Aros S,Cremonini F,Talley NJ.Treatment of functional dyspepsia.Curr Treat Options Gastroenterol,2004,7:121-131.
  • 9Sheu BS,Yang HB,Sang YL,et al.Pretreatment gastric histology is helpful to predict the symptomatic response after H.pylori eradication in patients with nonulcer dyspepsia.Dig Dis Sci,2001,46:2700-2707.
  • 10Whitaker MJ,Brun J,Carilli F.Controversy and consensus in themanagement of uppergastrointestinal disease in primary care.Int J Clin Pract,1997,51:239-243.

同被引文献193

引证文献17

二级引证文献461

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部